Suramin for Acute Kidney Injury

Recruiting at 11 trial locations

Overseen By Jeremy Whitson

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Rediscovery Life Sciences

Must not be taking: Vasopressors, Warfarin

Disqualifiers: Dialysis, Renal transplant, Hepatitis, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 1 day

68 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are on warfarin, you must be on stable long-term therapy. It's best to discuss your specific medications with the trial team.

What evidence supports the effectiveness of the drug Suramin for treating acute kidney injury?

Research suggests that Suramin, when used with mouse adult renal progenitor cells, can help reduce kidney damage and promote recovery in animal models of acute kidney injury. This combination therapy shows promise as a potential new strategy for treating this condition. ^{1 2 3 4 5}

How does the drug Suramin differ from other treatments for acute kidney injury?

Suramin is unique because it can be administered after kidney injury has occurred, helping to reduce inflammation and promote kidney repair by decreasing harmful proteins and increasing cell proliferation. Unlike other treatments, it was originally developed for parasitic infections and has shown potential in reducing kidney damage and improving recovery in animal studies. ^{6 7 8 9 10}

What is the purpose of this trial?

This trial is testing suramin, a medication, to see if it can help people with acute kidney injury (AKI) avoid worsening kidney problems. The goal is to prevent their condition from progressing to a severe stage or needing dialysis. Suramin works by blocking harmful processes that can damage the kidneys.

Eligibility Criteria

Adults with early-stage acute kidney injury (AKI) who haven't responded to a diuretic called furosemide are eligible. They must not have severe liver issues, be on multiple blood pressure medications, or have certain infections like HIV or COVID-19. A negative pregnancy test is required for women of childbearing age.

Inclusion Criteria

If female of childbearing potential, must have a negative pregnancy test at Screening

Is capable of providing informed consent as described in this protocol.

Your kidneys are not working well, and your blood test shows that a specific substance called creatinine has increased by a certain amount within 48 hours.

Exclusion Criteria

You have severe liver disease or signs of liver and kidney problems.

Unwilling to participate in follow-up phone surveys up to 180 days post-treatment

Are enrolled in another interventional research study or have participated in another interventional study within 14 days of Screening.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive a single 3.0 mg/kg infusion of suramin or placebo

1 day

Follow-up

Participants are monitored for safety and effectiveness after treatment

7 days

Treatment Details

Interventions

• Placebo
• Suramin

Trial Overview The study is testing Suramin against a placebo in patients with AKI to see if it can prevent worsening to Stage III AKI or the need for dialysis. Participants will be randomly assigned to receive either Suramin or a placebo without knowing which one they're getting.

Participant Groups

Group I: Suramin Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Rediscovery Life Sciences

Lead Sponsor

Trials

1

Recruited

70+

Findings from Research

Acute kidney injury (AKI) can lead to a range of outcomes, from complete recovery to chronic kidney disease or end-stage renal disease, highlighting the need for better understanding of the factors influencing these outcomes.

Recovery from AKI is a modifiable event, suggesting that targeted therapies and monitoring tools are essential for improving renal recovery and identifying patients at high risk for adverse outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical determinants of renal recovery. Godin, M., Macedo, E., Mehta, RL.[2015]

Currently, there are no specific therapies approved for the prevention or treatment of acute kidney injury (AKI), and traditional care remains largely supportive.

Recent research has identified various potential compounds targeting different pathways involved in AKI, such as oxidative stress and inflammation, which are now entering early-phase clinical trials, showing promise for future treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New drugs for acute kidney injury. Côté, JM., Murray, PT., Rosner, MH.[2021]

References

1. England pubmed.ncbi.nlm.nih.gov

Improving outcomes of acute kidney injury using mouse renal progenitor cells alone or in combination with erythropoietin or suramin. [2021]

2. England pubmed.ncbi.nlm.nih.gov

Mouse adult renal progenitor cells in combination with erythropoietin or suramin--a potential new strategy for the treatment of acute kidney injury. [2021]

3. Switzerland pubmed.ncbi.nlm.nih.gov

Clinical determinants of renal recovery. [2015]

4. United States pubmed.ncbi.nlm.nih.gov

New drugs for acute kidney injury. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Physiologic endpoints (efficacy) for acute renal failure studies. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

Suramin promotes recovery from renal ischemia/reperfusion injury in mice. [2013]

7. United States pubmed.ncbi.nlm.nih.gov

Recovery from glycerol-induced acute kidney injury is accelerated by suramin. [2022]

8. United States pubmed.ncbi.nlm.nih.gov

A pilot study of suramin in the treatment of metastatic renal cell carcinoma. [2019]

9. United States pubmed.ncbi.nlm.nih.gov

Suramin inhibits renal fibrosis in chronic kidney disease. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Acute renal failure in a patient receiving treatment with suramin. [2019]